Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex | Frankfurt | Healthcare | Biotechnology & Medical Research | €116.85B | -238.3x | 2.04 | €451.90 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vertex Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €116.85B | -238.3x | 2.04 | €453.05 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regeneron Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €67.76B | 16.9x | 1.67 | €626.40 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regeneron Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €67.76B | 16.9x | 1.67 | €636.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group | BATS Europe | Healthcare | Biotechnology & Medical Research | €40.66B | 67.1x | €562.83 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Argen-X | Brussels | Healthcare | Biotechnology & Medical Research | €32.65B | 41.9x | 0.13 | €536.80 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.3% Upside | Upgrade to Pro+ | |
argenx SE | Vienna | Healthcare | Biotechnology & Medical Research | €32.65B | 42.3x | 0.13 | €542 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
argenx | Frankfurt | Healthcare | Biotechnology & Medical Research | €32.63B | 42.3x | 0.13 | €538.40 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
arGEN X BV | BATS Europe | Healthcare | Biotechnology & Medical Research | €32.63B | 42.3x | 0.12 | €536.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings | Vienna | Healthcare | Biotechnology & Medical Research | €30.02B | 24.8x | 8.97 | €170 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biontech | Frankfurt | Healthcare | Biotechnology & Medical Research | €22.11B | -33.2x | 0.44 | €91.15 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | Xetra | Healthcare | Biotechnology & Medical Research | €22.11B | -33.2x | 0.44 | €91.50 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE DRC | Vienna | Healthcare | Biotechnology & Medical Research | €22.11B | -33.2x | 0.44 | €90 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Frankfurt | Healthcare | Biotechnology & Medical Research | €12.43B | -3.8x | -0.16 | €31.64 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Xetra | Healthcare | Biotechnology & Medical Research | €12.43B | -3.8x | -0.16 | €31.76 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Vienna | Healthcare | Biotechnology & Medical Research | €12.43B | -3.8x | -0.16 | €31.67 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Milan | Healthcare | Biotechnology & Medical Research | €12.43B | -3.8x | -0.16 | €31.60 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | Vienna | Healthcare | Biotechnology & Medical Research | €11.62B | 11.1x | 0.16 | €184.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | BATS Europe | Healthcare | Biotechnology & Medical Research | €11.59B | 11.2x | 0.16 | €185.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Exelixis | Frankfurt | Healthcare | Biotechnology & Medical Research | €9.56B | 20.6x | 0.12 | €33.77 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.26B | -22.1x | -0.9 | €137 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Vienna | Healthcare | Biotechnology & Medical Research | €7.78B | 105.2x | -1.34 | €36.08 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Milan | Healthcare | Biotechnology & Medical Research | €7.78B | 105.1x | -1.34 | €36.05 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Xetra | Healthcare | Biotechnology & Medical Research | €7.77B | 105.1x | -1.34 | €36.03 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.4% Upside | Upgrade to Pro+ | |
Qiagen NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €7.77B | 105.1x | -1.34 | €35.91 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.5% Upside | Upgrade to Pro+ | |
Qiagen NV | BATS Europe | Healthcare | Biotechnology & Medical Research | €7.77B | 105.1x | -1.28 | €36.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Blueprint Medicines | Frankfurt | Healthcare | Biotechnology & Medical Research | €5.31B | -84.4x | -0.95 | €81.28 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ionis Pharmaceuticals | Frankfurt | Healthcare | Biotechnology & Medical Research | €4.88B | -13.8x | 0.63 | €30.38 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merus NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €3.12B | -14.7x | 1.27 | €42.40 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Rhythm Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €2.98B | -11.8x | 0.34 | €46.20 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Denali Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €2.13B | -6.2x | 0.04 | €14.51 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech AG BATS | BATS Europe | Healthcare | Biotechnology & Medical Research | €2B | 25.6x | 0.19 | €36.75 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Xetra | Healthcare | Biotechnology & Medical Research | €2B | 25.6x | 0.19 | €36.60 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Frankfurt | Healthcare | Biotechnology & Medical Research | €2B | 25.6x | 0.19 | €36.75 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.60B | 21.8x | 20.35 | €25.26 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | Amsterdam | Healthcare | Biotechnology & Medical Research | €1.60B | 21.7x | 19.33 | €24.28 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.2% Upside | Upgrade to Pro+ | |
Galapagos NV | Vienna | Healthcare | Biotechnology & Medical Research | €1.60B | 21.8x | 19.33 | €24.56 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.49B | -309.2x | 2.81 | €22.80 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.49B | -309.2x | 2.81 | €22.70 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viridian Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.25B | -5.5x | -0.29 | €15 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novavax | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.20B | -6.6x | -0.1 | €7.32 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novavax | Vienna | Healthcare | Biotechnology & Medical Research | €1.20B | -6.6x | -0.09 | €7.28 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec AG | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.17B | -6.9x | 0.08 | €6.78 | -17.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Iovance Biotherapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.15B | -3x | -0.1 | €3.48 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec AG | Xetra | Healthcare | Biotechnology & Medical Research | €1.09B | -6.3x | 0.09 | €6.14 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.09B | -6.3x | 0.09 | €6.17 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Vienna | Healthcare | Biotechnology & Medical Research | €1.09B | -6.3x | 0.09 | €6.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Syndax Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.04B | -3.6x | 0.15 | €11.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CareDx | Frankfurt | Healthcare | Biotechnology & Medical Research | €965.29M | 19x | 0.16 | €17.19 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Intellia Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €914.38M | -1.8x | -0.66 | €8.43 | -8.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |